Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial
Michael P. Manns(Medizinische Hochschule Hannover), Didier Samuel(Université Paris-Sud), Edward Gane(Auckland City Hospital), David Mutimer(NIHR Birmingham Liver Biomedical Research Unit), Geoffrey W. McCaughan(Royal Prince Alfred Hospital), Marı́a Buti(Centro de Investigación Biomédica en Red), M. Prieto(Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas), José Luís Calleja(Hospital Universitario Puerta de Hierro Majadahonda), Markus Peck‐Radosavljevic(Medical University of Vienna), Beat Müllhaupt, Kosh Agarwal(King's College Hospital NHS Foundation Trust), Peter Angus(Austin Hospital), Eric M. Yoshida(Vancouver General Hospital), Massimo Colombo(University of Milan), Mario Rizzetto, Hadas Dvory‐Sobol(Gilead Sciences (United States)), Jill Denning(Gilead Sciences (United States)), Sarah Arterburn(Gilead Sciences (United States)), Phillip S. Pang(Gilead Sciences (United States)), Diana M. Brainard(Gilead Sciences (United States)), John G. McHutchison(Gilead Sciences (United States)), Jean‐François Dufour(University of Bern), Hans Van Vlierberghe(Ghent University Hospital), Bart van Hoek(Leiden University Medical Center), Xavier Forns(Universitat de Barcelona)
Cited by 446Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis